Literature DB >> 32856275

Novel [l,2,4]triazolo[3,4-a]isoquinoline chalcones as new chemotherapeutic agents: Block IAP tyrosine kinase domain and induce both intrinsic and extrinsic pathways of apoptosis.

Magda F Mohamed1,2, Farid M Sroor3, Nada S Ibrahim4, Ghada S Salem5, Hadeer H El-Sayed5, Marwa M Mahmoud5, Menna-Allah M Wagdy5, Amina M Ahmed5, Aya-Allah T Mahmoud5, Somia S Ibrahim5, Mariam M Ismail5, Sanaa Mohy Eldin6, Fatma M Saleh7, Hamdi M Hassaneen7, Ismail A Abdelhamid7.   

Abstract

Two novel chemotherapeutic chalcones were synthesized and their structures were confirmed by different spectral tools. Theoretical studies such as molecular modeling were done to detect the mechanism of action of these compounds. In vitro cytotoxicity showed a strong effect against all tested cell lines (MCF7, A459, HepG2, and HCT116), and low toxic effect against normal human melanocytes (HFB4). The lung carcinoma cell line was chosen for further molecular studies. Real-time PCR demonstrated that the two compounds upregulated gene expression of (BAX, p53, casp-3, casp-8, casp-9) genes and decreased the expression of anti-apoptotic genes bcl2, CDK4, and MMP1. Flow-cytometry indicated that cell cycle arrest of A459 was induced at the G2/M phase and the apoptotic percentage increased significantly compared to the control sample. Cytochrome c oxidase and VEGF enzyme activity were detected by ELISA assay. SEM tool was used to follow the morphological changes that occurred on the cell surface, cell granulation, and average roughness of the cell surface. The change in the number and morphology of mitochondria, cell shrinkage, increase in the number of cytoplasmic organelles, membrane blebbing, chromatin condensation, and apoptotic bodies were observed using TEM. The obtained data suggested that new chalcones exerted their pathways on lung carcinoma through induction of two pathways of apoptosis. Graphical abstract Novel chalcones were prepared and confirmed by different spectral tools. Docking simulations were done to detect the mechanism of action. In vitro cytotoxicity indicated a strong effect against different cancer cell lines and low toxic effects against normal human melanocytes (HFB4). The lung carcinoma cell line was chosen for further molecular studies that include Real-time PCR, Flow-cytometry, Cytochrome c oxidase, and ELISA assay. SEM and TEM tool were used to follow the morphological changes occurred on the cell surface.

Entities:  

Keywords:  Chalcones; Cytochrome c oxidase; Cytotoxicity; IAP-Caspase3; Morphological characterization; [l,2,4]Triazolo[3,4-a]isoquinoline

Mesh:

Substances:

Year:  2020        PMID: 32856275     DOI: 10.1007/s10637-020-00987-2

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  34 in total

1.  Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.

Authors:  Piyush N Kalaria; Shailesh P Satasia; Dipak K Raval
Journal:  Eur J Med Chem       Date:  2014-03-19       Impact factor: 6.514

2.  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.

Authors:  Kwai-Ming J Cheung; Thomas P Matthews; Karen James; Martin G Rowlands; Katherine J Boxall; Swee Y Sharp; Alison Maloney; S Mark Roe; Chrisostomos Prodromou; Laurence H Pearl; G Wynne Aherne; Edward McDonald; Paul Workman
Journal:  Bioorg Med Chem Lett       Date:  2005-07-15       Impact factor: 2.823

3.  Anticancer effect of three pyrazole derivatives.

Authors:  Ibrahim Bouabdallah; Lahcen Ait M'Barek; Abdelmajid Zyad; Abdelkrim Ramdani; Ismail Zidane; Ahmed Melhaoui
Journal:  Nat Prod Res       Date:  2006-09       Impact factor: 2.861

4.  Discovery of a potent and selective series of pyrazole bacterial methionyl-tRNA synthetase inhibitors.

Authors:  John Finn; Karen Mattia; Mike Morytko; Siya Ram; Yingfei Yang; Ximao Wu; Elsa Mak; Paul Gallant; Dennis Keith
Journal:  Bioorg Med Chem Lett       Date:  2003-07-07       Impact factor: 2.823

5.  N'-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity.

Authors:  Darpan Kaushik; Suroor Ahmad Khan; Gita Chawla; Suresh Kumar
Journal:  Eur J Med Chem       Date:  2010-06-01       Impact factor: 6.514

6.  Synthesis and mechanism of action of novel pyrimidinyl pyrazole derivatives possessing antiproliferative activity.

Authors:  Hitoshi Ohki; Kenji Hirotani; Hiroyuki Naito; Satoru Ohsuki; Megumi Minami; Akio Ejima; Yukiko Koiso; Yuichi Hashimoto
Journal:  Bioorg Med Chem Lett       Date:  2002-11-04       Impact factor: 2.823

7.  Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring.

Authors:  Akihiko Tanitame; Yoshihiro Oyamada; Keiko Ofuji; Mika Fujimoto; Kenji Suzuki; Tomohiko Ueda; Hideo Terauchi; Motoji Kawasaki; Kazuo Nagai; Masaaki Wachi; Jun-ichi Yamagishi
Journal:  Bioorg Med Chem       Date:  2004-11-01       Impact factor: 3.641

8.  Stereoselective synthesis and antifungal activities of (E)-alpha-(methoxyimino)benzeneacetate derivatives containing 1,3,5-substituted pyrazole ring.

Authors:  Yan Li; Hong-Quan Zhang; Jie Liu; Xiang-Ping Yang; Zhao-Jie Liu
Journal:  J Agric Food Chem       Date:  2006-05-17       Impact factor: 5.279

9.  Cinnamoyl nitrogen mustard derivatives of pyrazole analogues of tallimustine modified at the amidino moiety: design, synthesis, molecular modeling and antitumor activity studies.

Authors:  Pier Giovanni Baraldi; Italo Beria; Paolo Cozzi; Cristina Geroni; Antonio Espinosa; Miguel A Gallo; Antonio Entrena; John P Bingham; John A Hartley; Romeo Romagnoli
Journal:  Bioorg Med Chem       Date:  2004-07-15       Impact factor: 3.641

10.  Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives.

Authors:  Daniele Zampieri; Maria Grazia Mamolo; Erik Laurini; Giuditta Scialino; Elena Banfi; Luciano Vio
Journal:  Bioorg Med Chem       Date:  2008-02-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.